Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple

A Deutsche Bank analyst forecasts the biopharma's stock could rise by more than 230% driven by two drugs for treatment‑resistant depression. The call is an analyst-driven upside projection rather than new clinical or regulatory data, so upside is speculative and hinges on trial/approval execution. Manage risk via cautious position sizing and monitor catalysts (trial readouts, regulatory milestones) before reallocating capital.

Analysis

A Deutsche Bank analyst forecasts the biopharma's stock could rise by more than 230% driven by two drugs for treatment‑resistant depression. The call is an analyst-driven upside projection rather than new clinical or regulatory data, so upside is speculative and hinges on trial/approval execution. Manage risk via cautious position sizing and monitor catalysts (trial readouts, regulatory milestones) before reallocating capital.